Albuquerque, NM March 19, 2007 -- A recent study published in the Journal of the American Medical Association questions the efficacy of CT scans for the early detection of lung cancer and its relationship to improved mortality rates. This is further evidence that the first-step, non-invasive screening test developed by Biomoda will be an essential tool for more accurate detection and treatment of lung cancer, said John Cousins, President of Biomoda, Inc. (www.biomoda.com) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology. Biomoda, Inc. trades on NASDAQ’s OTC Bulletin Board under the ticker symbol “BMOD”.
